BNF March 2023 Update

This update contains 3 significant changes, 2 dose changes, 4 new monographs, and 1 new preparation.

Significant Changes:

• Genital system infections, antibacterial therapy: updated guidance for the management of uncomplicated genital chlamydia and non-gonococcal urethritis.
• Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events [MHRA/CHM advice].
• Osteoarthritis: updated guidance on management.

Dose Change:

• Azithromycin [update to dosing for uncomplicated genital chlamydia in children from 12 years old and adults, update to dosing for non-gonococcal urethritis in adults, and update to include dosing in children from 12 years old for uncomplicated gonorrhoea].
• Ceftriaxone [update to dosing for pelvic inflammatory disease].

New Monographs:

• Lunsumio® [mosunetuzumab].
• Rapibloc® [landiolol hydrochloride].
• Tezspire® [tezepelumab].
• Xenpozyme® [olipudase alfa].

New Preparations:
• Okedi® [risperidone].